Mirum Pharmaceuticals, Inc. (MIRM) Misses Q2 EPS by 122c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($1.94), $1.22 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $37.5 million versus the consensus estimate of $30.23 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
• Bit Digital (BTBT) Misses Q2 EPS by 27c